

# CURRICULUM VITAE

*SCOTT D. PENDERGAST, MD*

## OFFICE ADDRESSES

Retina Associates of Cleveland, Inc.  
690 White Pond Drive, Suite 120; Akron, Ohio 44320  
3401 Enterprise Parkway, Suite 300; Beachwood, Ohio 44122  
4690 Munson Street NW; Canton, Ohio 44718  
340 Oxford Street, Suite 210; Dover, Ohio 44622  
6100 South Broadway Avenue, Suite 200; Lorain, Ohio 44052  
9485 Mentor Avenue, Suite 211; Mentor, Ohio 44060  
15299 Bagley Road, Suite 200; Middleburg Heights, Ohio 44130  
17534 Royalton Road, Suite 201; Strongsville, Ohio 44136  
170 North Road NE; Warren, Ohio 44483  
4350 Crocker Road, Suite 200; Westlake, Ohio 44145  
5390 Belmont Avenue; Youngstown, Ohio 44505

## TELEPHONE

216-831-5700

## WEBSITE

[www.retina-doctors.com](http://www.retina-doctors.com)

## EDUCATION

### *College*

Case Western Reserve University  
Cleveland, Ohio  
1986, BA *cum laude* (Biochemistry and Philosophy)

### *Medical School*

Boston University School of Medicine  
Boston, Massachusetts  
1991, MD *magna cum laude*

## POSTGRADUATE TRAINING

### *Internship*

Internal Medicine  
New England Deaconess Hospital  
Boston, Massachusetts  
1991–1992

### *Residency*

Ophthalmology  
Duke University Eye Center  
Durham, North Carolina  
1992–1995

*Fellowship*                      Vitreoretinal Diseases and Surgery  
Associated Retinal Consultants, PC  
Royal Oak, Michigan  
1995–1997

## LICENSURE AND BOARD CERTIFICATION

Licensed to practice medicine in Ohio

Diplomate, American Board of Ophthalmology, 1997; recertified 2008-2017, 2018-2027

## PROFESSIONAL POSITIONS

Retina Associates of Cleveland, 1997–

Practice limited to retinal diseases and surgery. Associates: Lawrence J. Singerman, MD; Michael A. Novak, MD; Hernando Zegarra, MD; Z. Nicholas Zakov, MD; David G. Miller, MD; Joseph M. Coney, MD; Jerome P. Schartman, MD; Llewelyn J. Rao, MD; Arnold F. Nothnagel, DO; Shawn A. Lewis, MD; Sean M. Platt, MD

## ACADEMIC AND TEACHING ACTIVITIES

The Retinal Institute, Mt Sinai Medical Center, Cleveland, Ohio; 1997–1998  
Vitreoretinal surgeon, Attending in Resident Clinic

The Eye Research Institute, Oakland University, Rochester, Michigan; 1996–1997  
Research Fellow

Harvard University, Boston, Massachusetts; 1991–1992  
Clinical Fellow in Medicine

## HONORS AND AWARDS

*Best Doctors in America*, 2013-2018

Haas Award Grant, 1997

Horwitz Prize, 1996 (first prize for best research presentation, Wm. Beaumont Hospital)

Heed Ophthalmic Foundation Fellowship, 1995

Unrestricted grant from Research to Prevent Blindness, Inc., 1993

Hewlett-Packard Company Medical Award (for top five students in graduating class), 1991

John M. Murray Prize (for best four-year performance in psychiatry), 1991

Alpha Omega Alpha, junior year, 1990

Institute of Pathology Research Fellowship, 1985

## MEMBERSHIPS

The Academy of Medicine of Cleveland  
American Academy of Ophthalmology

American Society of Retinal Specialists (formerly the Vitreous Society)  
American Medical Association  
Association for Research in Vision and Ophthalmology  
Cleveland Ophthalmological Society  
Heed Ophthalmic Foundation  
Ohio State Medical Association

## HOSPITAL & ASC AFFILIATIONS

Cleveland Eye and Laser Surgery Center; Cleveland, Ohio  
Brainard Surgery Center; Cleveland, Ohio  
Summa Healthcare System; Akron, Ohio  
Surgery Center of Canfield; Canfield, Ohio

## RESEARCH ACTIVITIES

### *NIH-funded Grants*

*Home vision monitoring in AREDS2 for progression to neovascular age-related macular degeneration*

Co-investigator, 2011–2013

*Comparison of age-related macular degeneration treatments trials: Lucentis-Avastin trial (CATT)*

Co-investigator, 2008–2012

*Age-Related Eye Disease Study (AREDS) 2*

Co-investigator, 2006–2012

*Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study*

Co-investigator, 2004–2009

*Family Investigation of Nephropathy and Diabetes – FIND*

Co-investigator/Study Ophthalmologist. 2000–

*Epidemiology of Diabetes Interventions and Complications Trial – EDIC*

Co-investigator, 1998–

*Complications of Age-related Macular Degeneration Prevention Trial – Laser treatment of drusen – CAPT*

Co-investigator, 1998–2007

*Collaborative Ocular Melanoma Study (COMS)*

Following and Enucleating Ophthalmologist, 1997–2003

*Submacular Surgery Trials*

Co-investigator, 1997–2004

**Other National Clinical Trials**

*Phase 2b dose-ranging study of pazopanib eye drops versus ranibizumab intravitreal injections for the treatment of neovascular age-related macular degeneration*

Principal Investigator, 2010–2011

*Eyetech 1023: Phase IV, open label, multicenter trial of maintenance intravitreal injections of Macugen® (pegaptanib sodium) given every 6 weeks for 48 weeks in subjects with subfoveal neovascular age-related macular degeneration (AMD) initially treated with a modality resulting in maculopathy improvement*

Principal investigator, 2006–2008

*Eyetech 1012: Phase 4, randomized, active controlled, double-masked, single dummy, to compare the safety and efficacy of Macugen every 6 weeks plus sham PDT to Macugen every 6 weeks with PDT in patients with predominantly classic CNV*

Principal investigator, 2005–2006

*Eyetech 1011: A Phase II randomized, double-masked, safety, efficacy, and pharmacokinetics study of Macugen vs. placebo given every 6 weeks for 30 weeks for vision loss due to macular edema secondary to CRVO*

Principal investigator, 2004–2006

*EyeTech 1009: A Phase II prospective, randomized, double-masked, sham controlled, dose-ranging, multi-center trial to assess the effect of pegaptanib sodium on fovea thickening in patients with exudative subfoveal age-related macular degeneration*

Principal investigator, 2004–2006

*Eyetech 1010: Open label, non-comparative protocol for use of 0.3mg intravitreal Macugen injections every 6 weeks in patients with AMD*

Principal investigator, 2004–2005

*EyeTech 1006: A randomized, double-masked, multi-center trial of the safety, tolerability and pharmacokinetics of 1 mg/eye and 3 mg/eye intravitreal injections of pegaptanib sodium (anti-VEGF PEGylated aptamer) given every 6 weeks for 54 weeks, in patients with exudative age-related macular degeneration*

Principal investigator, 2002–2006

*EyeTech 1005: A Phase II randomized, controlled, double-masked, dose-finding, multi-center, comparative trial, in parallel groups, to establish the safety and preliminary efficacy of intravitreal injections of EYE001 (anti-VEGF PEGylated aptamer), given every 6 weeks for 12 to 30 weeks to patients with clinically significant diabetic macular edema (CSME) involving the center of the macula*

Principal investigator, 2002–2003

*Fluocinolone Acetonide in Diabetic Macular Edema (FAME 4) Study: A multicenter, randomized, masked, controlled study to evaluate the safety and efficacy of Retisert™, an intravitreal fluocinolone acetonide implant, in the treatment of patients with diabetic macular edema*

Principal investigator, 2001–2007

*EyeTech 1004: Phase II/III randomized, double-masked, controlled, dose-ranging, multicenter comparative trial, in parallel groups, to establish the safety and efficacy of intravitreal injections of EYE001 (anti-VEGF PEGylated aptamer) given every 6 weeks for 54 weeks in patients with age-related macular degeneration*

Principal investigator, 2001–2005

*Vitrase® for Vitreous Hemorrhage Study*

Principal investigator, 1998–1999

*Phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of RO6867461 in patients with diabetic macular edema (YOSEMITE)*

Co-investigator, 2018–

*Two-year, three-arm, randomized, double-masked, multicenter, phase III study assessing the efficacy and safety of brolicizumab versus aflibercept in adult patients with visual impairment due to diabetic macular edema (KESTREL)*

Co-investigator, 2018–

*Phase 2b randomized, double-masked, controlled trial to assess the safety and efficacy of intravitreal administration of Zimura™ (anti-c5 aptamer) in subjects with geographic atrophy secondary to dry age-related macular degeneration*

Co-investigator, 2018–

*Phase III randomised, double-masked, parallel group, multicentre study to compare the efficacy, safety, pharmacokinetics and immunogenicity between SB11 and Lucentis® in subjects with neovascular age-related macular degeneration*

Co-investigator, 2018–

*Phase 2a study of OPT-302 in combination with aflibercept for persistent central-involved diabetic macular edema*

Co-investigator, 2017–

*Phase 2 double-masked, placebo-controlled study to assess the safety and efficacy of subcutaneously administered AKB-9778 15 mg once daily or 15 mg twice daily for 12 months in patients with moderate to severe non-proliferative diabetic retinopathy (TIME-2b study)*

Co-investigator, 2017–

*Phase III multicenter randomized, sham controlled, study to determine the safety and efficacy of Renexus® in macular telangiectasia type 2 (NTMT-03-A)*

Co-investigator, 2017–

*Efficacy and safety study of squalamine ophthalmic solution in subjects with neovascular AMD (MAKO)*

Co-investigator, 2016–

*Phase II, multicenter, randomized, single-masked, sham-controlled study of safety, tolerability and evidence of activity of intravitreal APL-2 therapy in patients with geographic atrophy (GA)*

Co-investigator, 2015–

*Phase III double masked study of safety and efficacy of abicipar pegol in patients with neovascular age-related macular degeneration*

Co-investigator, 2015–2018

*Randomized, double-masked, multicenter, three-arm study comparing the efficacy and safety of RTH-258 versus aflibercept in subjects with neovascular age-related macular degeneration*

Co-investigator, 2015–2018

*Phase III, multicenter, randomized, double-masked, sham-controlled study to assess the efficacy and safety of lampalizumab administered intravitreally to patients with geographic atrophy secondary to age-related macular degeneration (PROXIMA)*

Co-investigator, 2015–2018

*Phase 3, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of Fovista (anti PDGF-B PEGylated aptamer) administered in combination with either Avastin or Eylea compared to Avastin or Eylea monotherapy in subjects with subfoveal neovascular age-related macular degeneration*

Co-investigator, 2015–2017

*An 18-month Phase 2a open label, randomized study of Avastin, Lucentis, or Eylea (anti-VEGF therapy) administered in combination with Fovista (anti-PDGF BB PEGylated aptamer)*

Co-investigator, 2015–2017

*A study of lampalizumab intravitreal injections administered every two weeks or every four weeks to patients with geographic atrophy (EXPOSURE)*

Co-investigator, 2015–2017

*LHA510 proof-of-concept study as a maintenance therapy for patients with wet age-related macular degeneration*

Co-investigator, 2015–2016

*A study investigating the efficacy and safety of lampalizumab intravitreal injections in patients with geographic atrophy secondary to age-related macular degeneration (CHROMA)*

Co-investigator, 2014–2018

*Phase 2, multi-center study to compare the efficacy and safety of a chemokine CCR2/5 receptor antagonist with ranibizumab in adults with diabetic macular edema*

Co-investigator, 2014–2015

*Phase 2 multicenter randomized clinical trial of ciliary neurotrophic factor (CNTF) for macular telangiectasia type 2 (MacTel)*

Co-investigator, 2013–

*Phase 3, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of Fovista (anti PDGF-B PEGylated aptamer) administered in combination with Lucentis compared to Lucentis monotherapy in subjects with subfoveal neovascular age-related macular degeneration*

Co-investigator, 2013–2017

*Phase 2b/3 multicenter, randomized, double-masked, dose-ranging study comparing the efficacy and safety of emixustat hydrochloride (ACU-4429) with placebo for the treatment of geographic atrophy associated with dry age-related macular degeneration (SEATTLE)*

Co-investigator, 2013–2016

*Prospective, randomized, double-masked, multicenter, two arm study comparing the efficacy and safety of ESBA1008 versus Eylea® in subjects with exudative age-related macular degeneration*

Co-investigator, 2013–2014

*Efficacy and safety of squalamine lactate eye drops in subjects with neovascular (wet) age-related macular degeneration*

Co-investigator, 2012–2015

*Ocriplasmin for treatment for symptomatic vitreomacular adhesion including macular hole (OASIS)*

Co-investigator, 2012–2014

*Safety and tolerability of intravenous LFG316 in wet age-related macular degeneration*

Co-investigator, 2012–2013

*Single and repeat dose study of the safety and efficacy of AGN-150998 in patients with exudative age-related macular degeneration*

Co-investigator, 2012

*Phase 1 multicenter open-label safety and tolerability clinical trial of ciliary neurotrophic factor (CNTF) in patients with macular telangiectasia Type 2 (MacTel)*

Co-investigator, 2011–2016

*A study of safety, tolerability, and evidence of activity of FCFD4514S administered monthly or every other month to patients with geographic atrophy*

Co-investigator, 2011–2013

*Phase 2, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal injections of E10030 (anti-PDGF PEGylated aptamer) given in combination with Lucentis® in subjects with neovascular age-related macular degeneration*

Co-investigator, 2010–2011

*Impact of Lucentis on psychological morbidity in patients with macular edema and neovascularization secondary to retinal vein occlusion*

Co-investigator, 2009–2012

*Geographic Atrophy Treatment Evaluation (GATE) Study*

Co-investigator, 2009–2012

*Phase 1, single ascending dose and parallel group trial to establish the safety, tolerability, and pharmacokinetic profile of multiple intravitreal injections of volociximab ( $\alpha 5\beta 1$  integrin antagonist) as monotherapy or given in combination with Lucentis 0.5mg/eye in subjects with neovascular AMD (Ophthotech 3000)*

Co-investigator, 2008–2012

*Phase 2, randomized, double-masked, placebo-controlled, dose-ranging clinical study to assess the safety and efficacy of subconjunctival injections of sirolimus in patients with diabetic macular edema secondary to diabetic retinopathy*

Co-investigator, 2008–2010

*Anecortave acetate for treatment of steroid- induced intraocular pressure (IOP) elevation*

Co-investigator, 2008–2010

*Natural History of Geographic Atrophy Progression (GAP) Study*

Co-investigator, 2008–2009

*Safety and efficacy of 700ug dexamethasone posterior segment drug delivery system (DEXDDS) applicator system in combination with laser photocoagulation compared with laser photocoagulation alone in the treatment of diffuse macular edema (DME)*

Co-investigator, 2008–2009

*A study of ranibizumab injection in subjects with clinically significant with macular edema center involvement secondary to diabetes mellitus (RIDE)*

Co-investigator, 2007–2012

*A multicenter, randomized, placebo-controlled, double-masked, parallel group, dose-ranging clinical trial of intravitreal microplasmin in patients undergoing surgical vitrectomy: The MIVI III (Microplasmin For Vitreous Injection III) Trial*

Co-investigator, 2007–2010

*Sirion Phase II randomized, double-masked, placebo-controlled, dose-comparison study of the safety and efficacy of fenretinide in the treatment of geographic atrophy in age-related macular degeneration*

Co-investigator, 2007–2010



*Indocyanine green (ICG) angiographic evaluation of ranibizumab (Lucentis®) treatment of pigment epithelial detachment (PED) associated with age-related macular degeneration (AMD)*  
Co-investigator, 2007–2009

*OMEGA: A randomized, double-masked, dose-ranging, multi-center, phase II study comparing the safety and efficacy of OT-551 with placebo to treat geographic atrophy associated with age-related macular degeneration*  
Co-investigator, 2007–2009

*Age-related Macular Degeneration: Detection of Onset of new Choroidal neovascularization (AMD DOC) study comparing preferential hyperacuity perimetry (PHP) with supervised Amsler grid in detecting AMD for earlier treatment in high-risk fellow eyes (Johns Hopkins)*  
Co-investigator, 2007–2009

*Phase 1, single ascending dose trial to establish the safety, tolerability, and pharmacokinetic profile of intravitreal injections of E10030 (anti-PDGF PEGylated aptamer) monotherapy and of E10030 given in combination with Lucentis 0.3mg/eye in subjects with neovascular AMD*  
Co-investigator, 2007–2008

*COBALT: COmbining Bevasiranib And Lucentis Therapy. A phase III, randomized, double-masked, parallel-assignment study of intravitreal bevasiranib sodium, administered every 8 or 12 weeks as maintenance therapy following three injections of Lucentis®, compared with Lucentis® monotherapy every 4 weeks in patients with exudative age-related macular degeneration (AMD)*  
Co-investigator, 2007–2008

*Small Interfering RNA In Macular Degeneration Study (SIRIUS): A 2 year, multicenter, randomized, controlled, masked, dose-finding trial to assess the safety and efficacy of multiple intravitreal injections of AGN211745 in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration*  
Co-investigator, 2007–2008

*Denali: A 24-month randomized, double-masked, controlled, multicenter, phase IIIB study assessing safety and efficacy of verteporfin (Visudyne® photodynamic therapy administered in conjunction with ranibizumab (Lucentis™) versus ranibizumab (Lucentis™) monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration*  
Co-investigator, 2007

*Efficacy and safety of intravitreal injection of Macugen for recent onset neovascular lesions of AMD*  
Co-investigator, 2006–2008

*Phase III, multicenter, masked, randomized, sham controlled trial to assess the safety and efficacy of DEX PS DDS (700 micrograms, 350 micrograms, or placebo) in the treatment of patients with diabetic macular edema*

Co-investigator, 2006–2007

*Protocol FVF3689g (SAILOR): A Phase IIIb, multicenter study to evaluate the safety and tolerability of ranibizumab in naïve and previously treated subjects with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)*

Co-investigator, 2006–2007

*A multi-center, double-masked, randomized, vehicle-controlled, parallel group evaluation of the safety and efficacy of OT-551 ophthalmic solution to prevent formation or delay progression of nuclear cataract formation in post-vitreectomy patients*

Co-investigator, 2006–2007

*Protocol FVF3426g (HORIZON): An open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in subjects with subfoveal choroidal neovascularization (CNV) secondary to age related macular degeneration (AMD) who have completed the treatment phase of a Genentech-sponsored ranibizumab study*

Co-investigator, 2006–2007

*Natural history and registry study of macular telangiectasia (MacTel)*

Co-investigator, 2005–

*The effect of ruboxistaurin on clinically significant macular edema in patients with diabetes mellitus, as assessed by optical coherence tomography*

Co-investigator, 2005–2011

*Interval Dose Evaluation of Anecortave Acetate (IDEAA) Study (Alcon)*

Co-investigator, 2005–2008

*Cand5 Anti-VEGF RNAi Evaluation (CARE): Dose comparison of Cand5 for subfoveal choroidal neovascularization associated with wet age-related macular degeneration (Acuity Pharmaceuticals)*

Co-investigator, 2005–2007

*Phase III, multicenter, masked, randomized, sham controlled trial to assess the safety and efficacy of DEX PS DDS (700 micrograms, 350 micrograms, or placebo) in the treatment of patients with macular edema following central retinal vein occlusion or branch retinal vein occlusion*

Co-investigator, 2005–2007

*An open label study for the evaluation of tolerability of four dose levels of Cand5 (RNA-interference) administered by single intravitreal injection in patients with wet age-related macular degeneration*

Co-investigator, 2005–2007

*Ocular side effects of Cialis vs. Viagra vs. placebo*

Co-investigator, 2005–2006

*A 24-month randomized, double-masked, sham controlled, multicenter, phase IIIB study comparing photodynamic therapy with verteporfin (Visudyne<sup>®</sup>) plus two different dose regimens of intravitreal triamcinolone acetonide (1 mg and 4 mg) versus Visudyne<sup>®</sup> plus intravitreal pegaptanib (Macugen<sup>®</sup>) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration*

Co-investigator, 2005–2006

*Protein Kinase C  $\beta$  Inhibitor Study B7A-MC-MBDL. Reduction in the occurrence of center-threatening diabetic macular edema*

Co-investigator, 2004–2010

*Anecortave Acetate Risk-Reduction Trial (AART)*

Co-investigator, 2004–2008

*Visudyne Patient Registry*

Co-investigator, 2004–2007

*A Phase 1/2, randomized, masked, single and multiple-dose, sequential dose-escalation study of the safety and efficacy of AG-013958 in subjects with subfoveal choroidal neovascularization associated with age-related macular degeneration*

Co-investigator, 2004–2006

*A randomized, double-masked, placebo controlled, parallel group, multi-center, dose-ranging study of denufosol tetrasodium (INS37217) intravitreal injection in subjects with rhegmatogenous retinal detachment*

Co-investigator, 2004–2005

*Protocol FVF2587g: a Phase III, multicenter, randomized, double-masked, active treatment-controlled study of the efficacy and safety of rhuFabv2 (ranibizumab) compared with verteporfin (Visudyne<sup>®</sup>) photodynamic therapy in subjects with predominantly classic neovascular age-related macular degeneration*

Co-investigator, 2003–2006

*The Implantable Miniature Telescope (IMT<sup>™</sup>) in patients with central vision impairment associated with age-related macular degeneration or Stargardt's macular dystrophy*

Co-investigator, 2003–2005

*Intravitreal Steroid Injection Studies (ISIS)*

Co-investigator, 2002–2006

*Oculex Study: A phase 2 randomized, multicenter, dose-ranging, controlled, parallel-group trial to assess the safety and effectiveness of dexamethasone posterior segment drug delivery system (DEX PS DDS<sup>®</sup>) in the treatment of persistent macular edema*

Co-investigator, 2001–2003

*Transpupillary thermotherapy for the treatment of subfoveal occult choroidal neovascular membranes in patients with age-related macular degeneration*

Co-investigator, 2000–2004

*Verteporfin in Age-related Macular degeneration (VAM) Study: Open-label, multicenter, safety study of the treatment of predominantly classic choroidal neovascularization secondary to age-related macular degeneration using photodynamic therapy with verteporfin for injection*

Co-investigator, 1999–2000

*Verteporfin in Photodynamic Therapy Study*

Co-investigator, 1998–2003

*Protein kinase C  $\beta$  inhibitor studies: Diabetic Macular Edema Study and Diabetic Retinopathy Study*

Co-investigator, 1998–2002

*Evaluation of safety and duration of efficacy of anecortave acetate sterile suspension versus placebo following a single sub-Tenon's injection for the inhibition of neovascularization in patients with exudative age-related macular degeneration*

Co-investigator, 1998–2001

#### **SELECTED PRESENTATIONS AT LOCAL, NATIONAL, AND INTERNATIONAL MEETINGS AND SYMPOSIA**

1. New frontiers in the treatment of retinal degenerative disorders: stem cell therapy. Optometric Retinal Update Seminar. Warren, Ohio, August 22, 2018.
2. New frontiers in the management of dry AMD. Community Doctors Education Program. Warren, Ohio, September 6, 2017.
3. Clinical update on Fovista. Optometric Retinal Update Seminar. Warren, Ohio, September 1, 2015.
4. Retinal emergencies. Optometric Retinal Update Seminar. Warren, Ohio, September 10, 2013.
5. Evaluation and treatment of retinal vein occlusion. Optometric Retinal Update Seminar. Beachwood, Ohio, March 25, 2010.
6. Retinal emergencies. Optometric Retinal Update Seminar. Beachwood, Ohio, February 18, 2009.
7. Retinal emergencies. Optometric Retinal Update Seminar. Youngstown, Ohio, September 18, 2008.
8. Interesting retinal vascular cases. Optometric Retinal Update Seminar. Beachwood, Ohio,

February 21, 2008.

9. Role of anti-VEGF agents in retinal disorders. Optometric Retinal Update Seminar. Youngstown, Ohio, September 5, 2007.
10. Update on Lucentis and Avastin in the treatment of neovascular age-related macular degeneration. Optometric Retinal Update Seminar. Beachwood, Ohio, February 15, 2007.
11. Update on anti-VEGF therapies in age-related macular degeneration. Optometric Retinal Update Seminar. Beachwood, Ohio, September 25, 2006.
12. The role of anti-VEGF therapy for the treatment of exudative AMD. Association of Indian Physicians of Northern Ohio Continuing Medical Education Seminar. Cleveland, Ohio, April 15, 2006.
13. Retinal degenerations. Optometric Retinal Update Seminar. Beachwood, Ohio, February 9, 2006.
14. Hereditary vitreoretinal degenerations. University Hospitals of Cleveland Residents' Lecture. February 1, 2006.
15. Update on Visudyne therapy. Optometric Retinal Update Seminar. Boardman, Ohio, September 14, 2005.
16. The genetics of macular degeneration. Seminar on Age-related Macular Degeneration. Solon, Ohio. June 4, 2005.
17. Macugen for AMD: VISION study results and exploratory analysis. Meetings in Medicine CME Program. Albuquerque, New Mexico. May 20, 2005
18. Macugen for AMD: VISION Study results and exploratory analysis. Meetings in Medicine CME Program. Erie, Pennsylvania. May 3, 2005
19. S.D. Pendergast. Macugen for AMD: VISION Study results and exploratory analysis. Meetings in Medicine CME Program. Buffalo, New York. April 15, 2005
20. S.D. Pendergast. Vascular endothelial growth factor: its role in ocular disease and implications for therapeutic intervention. Case Western Reserve University / University Hospitals of Cleveland, Department of Ophthalmology Grand Rounds. March 2, 2005.
21. Macugen for age-related macular degeneration: two year results. Optometric Retinal Update Seminar. Beachwood, Ohio. February 15, 2005.
22. VEGF and its role in AMD: Implications for therapeutics. Meetings in Medicine CME Program. Albany, New York. January 11, 2005.
23. The role of vascular endothelial growth factor in ocular disease. Meetings in Medicine CME Program. Columbus, Ohio. November 15, 2004.

24. Intravitreal Kenalog injection for cystoid macular edema. Optometric Retinal Update Seminar. Youngstown, Ohio. October 6, 2004.
25. Intravitreal Kenalog injection for cystoid macular edema. Optometric Retinal Update Seminar. Westlake, Ohio. July 29, 2004.
26. Intravitreal steroid injection for refractory cystoid macular edema. 37th Panhellenic Ophthalmological Congress. Porto Carras – Chalkidiki – Greece. June 9–13, 2004
27. Management of vasoproliferative and neovascular ocular disorder: case studies. Optometric Retinal Update Seminar. Beachwood, Ohio. February 19, 2004.
28. Implantable Miniature Telescope (IMT™): an update. Cleveland Ophthalmological Society Meeting. Independence, Ohio. February 10, 2004.
29. Implantable Miniature Telescope (IMT™): an update. Optometric Retinal Update Seminar. Westlake, Ohio. August 2003.
30. New treatments for diabetic macular edema. Optometric Retinal Update Seminar. Beachwood, Ohio. February 2003.
31. Intravitreal injection of anti-angiogenic agents for age-related macular degeneration. Inaugural Lorain County Optometric Retinal Update. Lorain, Ohio. November 2002.
32. Update on diabetic retinopathy. Third Annual Diabetes Seminar. Community Health Partners of Lorain, Lorain, Ohio. November 15, 2002.
33. Update on Diabetic Retinopathy. Optometric Retina Update Seminar. Beachwood, Ohio. February 2002.
34. Diagnosis and management of subfoveal choroidal neovascularization in a child with Coats disease. Cleveland Ophthalmological Society Meeting. Independence, Ohio.
35. New horizons in the treatment of diabetic retinopathy. The Diabetes Expo. Richfield, Ohio. November 1999.
36. Retinal manifestations of systemic disease. Ohio Eye Alliance Winter Seminar. Alliance, Ohio. November 1999.
37. Vitrectomy for the treatment of subfoveal choroidal neovascularization. Retina Update Seminar. Cleveland, Ohio. May 1999.
38. Submacular surgery for subfoveal choroidal neovascularization associated with age-related macular degeneration. Biannual Macular Degeneration Symposium, Cleveland, Ohio. April 1999.
39. Update on vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. Cleveland Ophthalmological Society Meeting.

- Independence, Ohio. December 1998.
40. Vitrectomy and silicone oil tamponade for serous macular detachment associated with a congenital optic pit in a child. Cleveland Ophthalmological Society Meeting. Independence, Ohio. October 1998.
  41. Vitrectomy for chronic pseudophakic cystoid macular edema. Club Vit Meeting. Vero Beach, Florida. April 1998.
  42. Masquerade syndrome – vitreous amyloidosis. Cleveland Ophthalmological Society Meeting. Independence, Ohio. April 1998.
  43. Lasers in the treatment of proliferative retinopathies. Eighth Annual Winter Eye Alliance. Canton, Ohio. February 1998.
  44. Pendergast SD, Hassan T, Cox M, Williams GA, et al. Vitrectomy for diffuse diabetic macular edema associated with a taut hyaloid membrane. Retina Society Annual Meeting. Vancouver, B.C. September 1997.
  45. Pendergast SD, Shastry BS, Trese MT. Identification of missense mutations in the Norrie's disease gene in infants with advanced retinopathy of prematurity. Vitreous Society Meeting. Cancun, Mexico. December 1996.
  46. Hassan T, Pendergast SD, Williams GA. Vitrectomy for diabetic macular edema associated with vitreomacular traction. Vitreous Society Meeting. Cancun, Mexico. December 1996.
  47. Ferrone PJ, Pendergast SD, Hartzler MK. The effects of scleral buckling on baby rabbit eyes. Vitreous Society Meeting. Cancun, Mexico. December 1996.
  48. Pendergast SD, Trese MT. Surgical management of familial exudative vitreoretinopathy. American Academy of Ophthalmology Meeting. October 29, 1996.
  49. Pendergast SD, Shastry BS, Hartzler MK, Trese MT. Identification of a missense mutation in the Norrie's disease gene associated with advanced retinopathy of prematurity. William Beaumont Hospital Research Forum. Royal Oak, Michigan, June 5, 1996.
  50. Pendergast SD, Hartzler MK, Dailey W, Williams GA, Cheng M, Trese MT. Fluid-gas exchange following intravitreal plasmin injection in a rabbit model. ARVO Meeting, Fort Lauderdale, Florida. April 22, 1996.
  51. Pendergast SD, McCuen BW II. Visual field loss following macular hole surgery. American Academy of Ophthalmology Meeting. Atlanta, Georgia. October 31, 1995.
  52. Pendergast SD, Shields MB. Reproducibility of optic nerve head topographical measurements with the Glaucoma-Scope. ARVO Meeting. Sarasota, Florida. May 4, 1994.

53. Pendergast SD, McCuen BW II, Martin DF, Proia AD, Jaffe GJ. Removal of optic disc stalks during diabetic vitrectomy. Vitreous Society Meeting. St. Thomas, U.S. Virgin Islands, December 1, 1993.

## PUBLICATIONS

### *Journal Articles*

1. Chew EY, Clemons TE, Jaffe GJ, Johnson CA, Farsiu S, Lad EM, Guymer R, Rosenfeld P, Hubschman JP, Constable I, Wiley H, Singerman LJ, Gillies M, Comer G, Blodi B, Elliott D, Yan J, Bird A, Friedlander M; Macular Telangiectasia Type 2-Phase 2 CNTF Research Group. Effect of ciliary neurotrophic factor on retinal neurodegeneration in patients with macular telangiectasia type 2: a randomized clinical trial. *Ophthalmology*. 2018 Oct 4. pii: S0161-6420(18)31427-1. doi: 10.1016/j.ophtha.2018.09.041. [Epub ahead of print]
2. Yu JJ, Agrón E, Clemons TE, Domalpally A, van Asten F, Keenan TD, Cukras C, Chew EY; Age-Related Eye Disease Study 2 Research Group. Natural history of drusenoid pigment epithelial detachment associated with age-related macular degeneration: Age-Related Eye Disease Study 2 report no. 17. *Ophthalmology*. 2018 Aug 22. pii: S0161-6420(18)31752-4. doi: 10.1016/j.ophtha.2018.08.017. [Epub ahead of print]
3. Keenan TD, Agrón E, Domalpally A, Clemons TE, van Asten F, Wong WT, Danis RG, Sadda S, Rosenfeld PJ, Klein ML, Ratnapriya R, Swaroop A, Ferris FL 3rd, Chew EY; AREDS2 Research Group. Progression of geographic atrophy in age-related macular degeneration: AREDS2 Report Number 16. *Ophthalmology*. 2018;125:1913-1928.
4. Purnell JQ, Braffett BH, Zinman B, Gubitosi-Klug RA, Sivitz W, Bantle JP, Ziegler G, Cleary PA, Brunzell JD; DCCT/EDIC Research Group. Impact of excessive weight gain on cardiovascular outcomes in Type 1 Diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. *Diabetes Care*. 2017;40:1756-1762.
5. DCCT/EDIC Research Group, Nathan DM, Bebu I, Hainsworth D, Klein R, Tamborlane W, Lorenzi G, Gubitosi-Klug R, Lachin JM. Frequency of evidence-based screening for retinopathy in Type 1 diabetes. *N Engl J Med*. 2017 Apr 20;376:1507-1516.
6. Chen Z, Miao F, Paterson AD, Lachin JM, Zhang L, Schones DE, Wu X, Wang J, Tompkins JD, Genuth S, Braffett BH, Riggs AD; DCCT/EDIC Research Group, Natarajan R. Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort. *Proc Natl Acad Sci U S A*. 2016;113(21):E3002-11.
7. Lenherr SM, Clemens JQ, Braffett BH, Cleary PA, Dunn RL, Hotaling JM, Jacobson AM, Kim C, Herman W, Brown JS, Wessells H, Sarma AV; DCCT/EDIC Research Group.



- Glycemic control and urinary tract infections in women with type 1 diabetes: Results from the DCCT/EDIC. *J Urol*. 2016;196:1129-1135.
8. Sharma S, Toth CA, Daniel E, Grunwald JE, Maguire MG, Ying GS, Huang J, Martin DF, Jaffe GJ; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Macular morphology and visual acuity in the second year of the Comparison of Age-Related Macular Degeneration Treatments Trials. *Ophthalmology*. 2016;123:865-875.
  9. Shah N, Maguire MG, Martin DF, Shaffer J, Ying GS, Grunwald JE, Toth CA, Jaffe GJ, Daniel E; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Angiographic cystoid macular edema and outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. *Ophthalmology*. 2016;123:858-864.
  10. AREDS2 Research Group, Al-Holou SN, Tucker WR, Agrón E, Clemons TE, Sperduto RD, Ferris FL 3rd, Chew EY. The association of statin use with cataract progression and cataract surgery: The AREDS2 Report Number 8. *Ophthalmology*. 2016;123:916-917.
  11. Daniel E, Shaffer J, Ying GS, Grunwald JE, Martin DF, Jaffe GJ, Maguire MG; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). *Ophthalmology*. 2016;123:609-616.
  12. Eny KM, Orchard TJ, Miller RG, Maynard J, Grant DM, Costacou T, Cleary PA, Braffett BH, Paterson AD; DCCT/EDIC Research Group. Caffeine consumption contributes to skin intrinsic fluorescence in type 1 Diabetes. *Diabetes Technol Ther*. 2015;17:726-734.
  13. Willoughby AS, Ying GS, Toth CA, Maguire MG, Burns RE, Grunwald JE, Daniel E, Jaffe GJ; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Subretinal hyperreflective material in the Comparison of Age-Related Macular Degeneration Treatments Trials. *Ophthalmology* 2015;122:1846-1853.
  14. Aref AA, Scott IU, Oden NL, Ip MS, Blodi BA, VanVeldhuisen PC; SCORE Study Investigator Group. Incidence, risk factors, and timing of elevated intraocular pressure after intravitreal triamcinolone acetonide injection for macular edema secondary to retinal vein occlusion: SCORE Study Report 15. *JAMA Ophthalmol*. 2015 Sep;133:1022-1029.
  15. Altaweel MM, Daniel E, Martin DF, Mitra RA, Grunwald JE, Lai MM, Melamud A, et al; Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). *Ophthalmology* 2015;122:391-398.
  16. Chew EY, Clemons TE, Peto T, Sallo FB, Ingerman A, Tao W, Singerman L, Schwartz SD, Peachey NS, Bird AC; MacTel-CNTF Research Group. Ciliary neurotrophic factor

- (CNTF) for macular telangiectasia Type 2 (MacTel): Results from a phase I safety trial. *Am J Ophthalmol* 2015;159:659-666.
17. Boyer DS, Goldbaum M, Leys AM, Starita C; for the V.I.S.I.O.N. Study Group. Effect of pegaptanib sodium 0.3 mg intravitreal injections (Macugen) in intraocular pressure: posthoc analysis from V.I.S.I.O.N. study. *Br J Ophthalmol* 2014 Nov;98:1543-1546.
  18. Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Maguire MG, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). *JAMA Ophthalmol* 2014;132:521-527.
  19. Kim BJ, Ying GS, Huang J, Levy NE, Maguire MG; CATT Research Group. Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). *Am J Ophthalmol*. 2014;158:128-135.
  20. Nathan DM, Bayless M, Cleary P, et al; DCCT/EDIC Research Group. Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions. *Diabetes* 2013;62:3976-3986.
  21. Maguire MG, Daniel E, Shah AR, Grunwald JE, et al; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT Research Group). Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. *Ophthalmology* 2013;120:2035-2041.
  22. Cheng CY, Schache M, Ikram MK, et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions, and Complications Research Group. Nine loci for ocular axial length identified through genome-wide association studies, including shared loci with refractive error. *Am J Hum Genet* 2013;93:264-277.
  23. Orchard TJ, Lyons TJ, Cleary PA, et al; DCCT/EDIC Research Group. The association of skin intrinsic fluorescence with type 1 diabetes complications in the DCCT/EDIC study. *Diabetes Care* 2013;36:3146-3153.
  24. Jacobson AM, Braffett BH, Cleary PA, Gubitosi-Klug RA, Larkin ME; DCCT/EDIC Research Group. The long-term effects of type 1 diabetes treatment and complications on health-related quality of life: a 23-year follow-up of the Diabetes Control and Complications/Epidemiology of Diabetes Interventions and Complications cohort. *Diabetes Care* 2013;36:3131-3138.
  25. Verhoeven VJ, Hysi PG, Wojciechowski R, et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Genome-wide meta-analyses of multi-ancestry cohorts identify multiple new susceptibility loci for refractive error and myopia. *Nat Genet* 2013;45:314-318.

26. Jaffe GJ, Martin DF, Toth CA, et al; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. *Ophthalmology* 2013;120:1860-1870.
27. Danis RP, Domalpally A, Chew EY, et al; AREDS2 Study Group. Methods and reproducibility of grading optimized digital color fundus photographs in the Age-Related Eye Disease Study 2 (AREDS2 Report Number 2). *Invest Ophthalmol Vis Sci* 2013;54:4548-4554.
28. Niskopoulou M, Balaskas K, Leung I, Sallo FB, Clemons TE, Bird AC, Peto T; MacTel Study group. Is indocyanine green angiography useful for the diagnosis of macular telangiectasia type 2? *Br J Ophthalmol* 2013;97:946-948.
29. Hagstrom SA, Ying GS, Pauer GJ, et al; Comparison of AMD Treatments Trials Research Group. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). *Ophthalmology* 2013;120:593-599
30. Ying GS, Huang J, Maguire MG, et al; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. *Ophthalmology* 2013 Jan;120:122-129.
31. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. *Ophthalmology* 2012;119:1388-1398.
32. DCCT/EDIC Research Group, de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Zinman B. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. *N Engl J Med* 2011;365:2366-2376.
33. Sallo FB, Leung I, Chung M, Wolf-Schnurrbusch UE, Dubra A, Williams DR, Clemons T, Pauleikhoff D, Bird AC, Peto T; MacTel Study Group. Retinal crystals in type 2 idiopathic macular telangiectasia. *Ophthalmology* 2011;118:2461-2467.
34. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM; Ozurdex GENEVA Study Group, Li J. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. *Ophthalmology* 2011;118:2453-2460.
35. Chan CK, Ip MS, Vanveldhuisen PC, Oden NL, Scott IU, Tolentino MJ, Blodi BA; SCORE Study Investigator Group. SCORE Study Report #11. Incidences of neovascular events in eyes with retinal vein occlusion. *Ophthalmology* 2011;118:1364-1372.

36. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration.. *N Engl J Med* 2011 May 19;364:1897-1908. Epub 2011 Apr 28.
37. Friberg TR, Tolentino M; LEVEL Study Group, Weber P, Patel S, Campbell S, Goldbaum M. Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study. *Br J Ophthalmol* 2010;94:1611-1617.
38. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM; OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. *Ophthalmology*. 2010;117:1134-1146.
39. Chen W, Stambolian D, Edwards AO, Branham KE, Othman M, Jakobsdottir J, Tosakulwong N, Pericak-Vance MA, Campochiaro PA, Klein ML, Tan PL, Conley YP, Kanda A, Kopplin L, Li Y, Augustaitis KJ, Karoukis AJ, Scott WK, Agarwal A, Kovach JL, Schwartz SG, Postel EA, Brooks M, Baratz KH, Brown WL; Complications of Age-Related Macular Degeneration Prevention Trial Research Group, Brucker AJ, Orlin A, Brown G, Ho A, Regillo C, Donoso L, Tian L, Kaderli B, Hadley D, Hagstrom SA, Peachey NS, Klein R, Klein BE, Gotoh N, Yamashiro K, Ferris Iii F, Fagerness JA, Reynolds R, Farrer LA, Kim IK, Miller JW, Cortón M, Carracedo A, Sanchez-Salorio M, Pugh EW, Doheny KF, Brion M, Deangelis MM, Weeks DE, Zack DJ, Chew EY, Heckenlively JR, Yoshimura N, Iyengar SK, Francis PJ, Katsanis N, Seddon JM, Haines JL, Gorin MB, Abecasis GR, Swaroop A. Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. *Proc Natl Acad Sci U S A*. 2010 Apr 20;107:7401-7406.
40. Ying GS, Maguire MG, Alexander J, Martin RW, Antoszyk AN; Complications of Age-related Macular Degeneration Prevention Trial Research Group. Description of the Age-Related Eye Disease Study 9-step severity scale applied to participants in the Complications of Age-related Macular Degeneration Prevention Trial. *Arch Ophthalmol*. 2009;127:1147-1151.
41. The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. *Arch Ophthalmol* 2009;127:1115-1128.
42. The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. *Arch Ophthalmol* 2009;127:1101-1114.

43. Ip MS, Oden NL, Scott IU, VanVeldhuisen PC, Blodi BA, Figueroa M, Antoszyk A, Elman M and the SCORE Study Investigator Group. SCORE Study Report 3: Study design and baseline characteristics. *Ophthalmology* 2009;116:1770–1777.
44. Clemons TE, Gillies MC, Chew EY, Bird AC, Peto T, Figueroa M, Harrington MW; Macular Telangiectasia Research Group. The National Eye Institute Visual Function Questionnaire in the Macular Telangiectasia (MacTel) Project. *Invest Ophthalmol Vis Sci* 2008;49:4340-4346.
45. Ying G-S, Maguire M, Liu C, Antoszyk A, Complications of Age-related Macular Degeneration Prevention Trial Research Group. Night vision symptoms and progression of age-related macular degeneration (AMD) in the Complications of AMD Prevention Trial. *Ophthalmology*. Epub 2008 Jul 30.
46. Complications of Age-related Macular Degeneration Prevention Trial (CAPT) Research Group. Risk factors for choroidal neovascularization and geographic atrophy in the complications of age-related macular degeneration prevention trial. *Ophthalmology* 2008;115:1474-1479, 1479.e1-6. Epub 2008 May 27.
47. Maguire MG, Alexander J, Fine SL; Complications of Age-related Macular Degeneration Prevention Trial (CAPT) Research Group. Characteristics of choroidal neovascularization in the complications of age-related macular degeneration prevention trial. *Ophthalmology* 2008;115:1468-1473, 1473.e1-2. Epub 2008 May 16.
48. Submacular Surgery Trials Research Group, Mann AL, Bressler SB, Hawkins BS, Holekamp N, Bressler NM. Comparison of methods to identify incident cataract in eyes of patients with neovascular maculopathy: Submacular Surgery Trials Report No. 18. *Ophthalmology* 2008;115:127-133. Epub 2007 Jun 14.
49. Macugen AMD Study Group, Apte RS, Modi M, Masonson H, Patel M, Whitfield L, Adamis AP. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. *Ophthalmology* 2007;114:1702-1712.
50. Submacular Surgery Trials Research Group, Solomon SD, Jefferys JL, Hawkins BS, Bressler NM. Incident choroidal neovascularization in fellow eyes of patients with unilateral subfoveal choroidal neovascularization secondary to age-related macular degeneration: SST report No. 20 from the Submacular Surgery Trials Research Group. *Arch Ophthalmol* 2007;125:1323-1330.
51. PKC-DMES Study Group. Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial. *Arch Ophthalmol* 2007;125:318-324.
52. Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, Whitcup SM; Dexamethasone DDS Phase II Study Group. Randomized controlled

- study of an intravitreal dexamethasone drug delivery system in patients with persistent macular edema. *Arch Ophthalmol* 2007;125:309-317.
53. Russell SR, Hudson HL, Jerdan JA; Anecortave Acetate Clinical Study Group. Anecortave acetate for the treatment of exudative age-related macular degeneration--a review of clinical outcomes. *Surv Ophthalmol* 2007;52 Suppl 1:S79-90.
  54. Complications of Age-related Macular Degeneration Prevention Trial Research Group. Laser treatment in patients with bilateral large drusen: The Complications of Age-Related Macular Degeneration Prevention Trial. *Ophthalmology* 113:1974-1986, 2006.
  55. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. *N Engl J Med* 355:1432-1444, 2006.
  56. Kuppermann BD, Thomas EL, de Smet MD, Grillone LR; Vitrase for Vitreous Hemorrhage Study Groups. Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreal injection of highly purified ovine hyaluronidase (Vitrase<sup>®</sup>) for the management of vitreous hemorrhage. *Am J Ophthalmol* 2005;140:573-584. [Epub ahead of print 2005Aug 26].
  57. Kuppermann BD, Thomas EL, de Smet MD, Grillone LR; Vitrase for Vitreous Hemorrhage Study Groups. Safety results of two phase III trials of an intravitreal injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. *Am J Ophthalmol* 2005;140:585-697.
  58. PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the protein kinase C {beta} inhibitor diabetic retinopathy study (PKC-DRS) multicenter randomized clinical trial. *Diabetes* 2005:2188-2197.
  59. Submacular Surgery Trials Research Group. Histopathological and ultrasound features of surgically excised subfoveal choroidal neovascular lesions. SST report no. 7. *Arch Ophthalmol* 2005;123:914-921.
  60. Submacular Surgery Trials Research Group. Guidelines for interpreting retinal photographs and coding findings in the Submacular Surgery Trials (SST). SST report no. 8. *Retina* 2005;25:253-268.
  61. Submacular Surgery Trials Research Group. Health-related quality of life among patients with ocular histoplasmosis or idiopathic choroidal neovascularization at enrollment in a randomized trial of submacular surgery. SST report no. 5. *Arch Ophthalmol* 2005;123:78-88.
  62. Childs AL, Submacular Surgery Trials Research Group. Effect of order of administration of health-related quality of life instruments on responses. SST report no. 3. *Qual Life Res* 2005;14:493-500.

63. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. *N Engl J Med* 2004;351:2805-2816.
64. Hawkins BS, Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. *Am J Ophthalmol* 2004;138:936-951.
65. Submacular Surgery Trials Research Group. Health- and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at time of enrollment in randomized trials of submacular surgery. SST report no. 4. *Am J Ophthalmol* 2004;138:91-108.
66. Submacular Surgery Trials Research Group. Patients' perceptions of the value of current vision: assessment of preference values among patients with subfoveal choroidal neovascularization--The Submacular Surgery Trials Vision Preference Value Scale: SST Report No. 6. *Arch Ophthalmol* 2004;122:1856-1867.
67. Submacular Surgery Trials Research Group. Surgical removal versus observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: II. Quality-of-life findings from a randomized clinical trial. SST Group H Trial. SST report no. 10. *Arch Ophthalmol* 2004;122:1616-1628.
68. Submacular Surgery Trials Research Group. Surgical removal versus observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: I. Ophthalmic findings from a randomized clinical trial: SST Group H Trial. SST Report No. 9. *Arch Ophthalmol* 2004;122:1597-1611.
69. Submacular Surgery Trials Research Group. Clinical trial performance of community-based compared with university-based practices: Lessons from the Submacular Surgery Trials. SST report no. 2. *Arch Ophthalmol* 2004;122:857-863
70. Pendergast SD, Ferrone PJ, Hartzler MK, Cheng M. The effects of scleral buckling on young rabbit eyes. *Arch Ophthalmol* 2004;122: 473-476.
71. Submacular Surgery Trials Research Group. Surgery for predominantly hemorrhagic choroidal neovascular lesions of age-related macular degeneration: Quality-of-life findings. SST report no. 14. *Ophthalmology* 2004;111:2007-2014.
72. Submacular Surgery Trials Research Group. Surgery for predominantly hemorrhagic choroidal neovascular lesions of age-related macular degeneration: Ophthalmic findings. SST report no. 13. *Ophthalmology* 2004;111:1993-2006.
73. Submacular Surgery Trials Research Group. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: Quality-of-life findings. SST report no. 12. *Ophthalmology* 2004;111:1981-1992.

74. Submacular Surgery Trials Research Group. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: Ophthalmic findings. SST report no. 11. *Ophthalmology* 2004;111:1967-1980.
75. Maguire M; Complications of Age-related Macular Degeneration Prevention Trial Research Group. Baseline characteristics, the 25-Item National Eye Institute Visual Functioning Questionnaire, and their associations in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT). *Ophthalmology* 2004;111:1307-1316.
76. Complications of Age-related Macular Degeneration Prevention Trial Study Group. The Complications of Age-related Macular Degeneration Prevention Trial (CAPT): rationale, design, and methodology. *Clinical Trials* 2004;1:91-107.
77. Collaborative Ocular Melanoma Study Group. Ten-year follow-up of fellow eyes of patients enrolled in Collaborative Ocular Melanoma Study (COMS) randomized trials. COMS Report No. 22. *Ophthalmology* 2004;111:966-976.
78. Azab M, Benchaboune M, Blinder KJ, et al; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group; Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4. *Retina* 2004;24:1-12.
79. D'Amico DJ, Goldberg MF, Hudson H, Jordan JA, Krueger S, Luna S, Robertson SM, Russell S, Singerman L, Slakter JS, Sullivan EK, Yannuzzi L, Zillion P; The Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. *Retina* 2003;23:14-23.
80. Straatsma BR, Diener-West M, Caldwell R, Engstrom RE; Collaborative Ocular Melanoma Study Group. Mortality after deferral of treatment or no treatment for choroidal melanoma. *Am J Ophthalmol* 2003;136:47-54.
81. D'Amico DJ, Goldberg MF, Hudson H, Jordan JA, Krueger DS, Luna SP, Robertson SM, Russell S, Singerman L, Slakter JS, Yannuzzi L, Zillion P; Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. *Ophthalmology* 2003;110:2372-2383.
82. The Submacular Surgery Trials Research Group. Responsiveness of the National Eye Institute Visual Function Questionnaire to changes in visual acuity: findings in patients with subfoveal choroidal neovascularization – SST Report No. 1. *Arch Ophthalmol* 2003;121:531-539.



83. The Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration. Phase II study results. *Ophthalmology* 2003;110:979-986.
84. Straatsma BR, Diener-West M, Caldwell R, Engstrom RE; Collaborative Ocular Melanoma Study Group.. Mortality after deferral of treatment or no treatment for choroidal melanoma. *Am J Ophthalmol* 2003;136:47-54.
85. Melia M, Moy CS, Reynolds SM, Cella D, Murray TG, Hovland KR, Hayman JA, Mangione CM; The Collaborative Ocular Melanoma Study-Quality of Life Study Group. Development and validation of disease-specific measures for choroidal melanoma: COMS-QOLS report No. 2. *Arch Ophthalmol* 2003;121:1010-1020.
86. Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. *Retina* 2002;22:143-152.
87. Collaborative Ocular Melanoma Study Group. Trends in size and treatment of recently diagnosed choroidal melanoma, 1987-1997: findings from patients examined at collaborative ocular melanoma study (COMS) centers: COMS Report No. 20. *Arch Ophthalmol* 2003;121:1156-1162.
88. Collaborative Ocular Melanoma Study Group. Comparison of clinical, echographic, and histopathological measurements from eyes with medium-sized choroidal melanoma in the collaborative ocular melanoma study: COMS Report No. 21. *Arch Ophthalmol* 2003;121:1163-1171.
89. The Collaborative Ocular Melanoma Study Group. The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS Report No. 19. *Ophthalmology* 2002;198:2197-2206.
90. The Collaborative Ocular Melanoma Study Group. Collaborative Ocular Melanoma Study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years. COMS Report No. 16. *Ophthalmology* 2001;108:348-366.
91. Collaborative Ocular Melanoma Study Group.. Cause-specific mortality coding: Methods in the Collaborative Ocular Melanoma Study. COMS Report No. 14. *Control Clin Trials* 2001;22:248-262.
92. The Collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS Report No. 15. *Arch Ophthalmol* 2001;119:670-676.

93. Grostern RJ, Slusker Shternfeld I, Bacus SS, Gilchrist K, Zimbric ML, Albert DM; Collaborative Ocular Melanoma Study Group. Absence of type I estrogen receptors in choroidal melanoma: analysis of Collaborative Ocular Melanoma Study (COMS) eyes. *Am J Ophthalmol* 2001;131:788-791.
94. Collaborative Ocular Melanoma Study Group. Collaborative Ocular Melanoma Study (COMS) randomized trial of 1-125 brachytherapy for choroidal melanoma. II. Characteristics of patients enrolled and not enrolled. COMS Report No. 17. *Arch Ophthalmol* 2001;119:951-965.
95. Collaborative Ocular Melanoma Study Group. Collaborative Ocular Melanoma Study (COMS) randomized trial of 1-125 brachytherapy for choroidal melanoma, III. Initial mortality findings. COMS Report No. 18. *Arch Ophthalmol* 2001;119:969-982.
96. Pendergast SD, Werner JC, Drevon AM, Wiedbrauk DL. Absence of herpesvirus DNA by polymerase chain reaction in ocular fluids obtained from immunocompetent patients. *Retina* 2000;20:389-393.
97. Pendergast SD, Hassan TS, Williams GA, Cox MS, Margherio RR, Ferrone PJ, Garretson BR, Trese MT. Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. *Am J Ophthalmol* 2000;130:178-186.
98. Submacular Surgery Trials Pilot Study Investigators. Submacular Surgery Trials randomized pilot trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration. I: Ophthalmic outcomes. Submacular Surgery Trials Pilot Study Report Number 1. *Am J Ophthalmol* 2000;130:387-407.
99. Submacular Surgery Trials Pilot Study Investigators. Submacular Surgery Trials randomized pilot trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration. II. Quality of life outcomes. Submacular Surgery Trials Pilot Study Report Number 2. *Am J Ophthalmol* 2000;130:408-418.
100. Pendergast SD, Margherio RR, Cox MS, Williams GA. Vitrectomy for chronic pseudophakic cystoid macular edema. *Am J Ophthalmol* 1999;128:317-323.
101. Collaborative Ocular Melanoma Study Group. Echography (ultrasound) procedures for the Collaborative Ocular Melanoma Study. COMS Report No. 12. *J Ophth Nurs Technol* 1999;Part I, 18(4):143-149, Part II, 18(5):219-232.
102. Hassan TS, Williams GA, and Pendergast SD. Vitrectomy for clinically significant macular edema. *Ophthalmic Practice* 1998;16:250.
103. Holck D, Pendergast SD, Klintworth GK, Dutton JJ. Double choroidal malignant melanoma in an eye with clinical regression. *Surv Ophthalmol* 1998;42:441-448.

104. Pendergast SD, Trese MT, Liu X, Shastry BS. Study of the Norrie disease gene in 2 patients with bilateral persistent hyperplastic primary vitreous. *Arch Ophthalmol* 1998;116:381-382.
105. Pendergast SD. Vitrectomy for diabetic macular edema associated with a taut premacular posterior hyaloid. *Current Opinion in Ophthalmology* 1998;111:71-75.
106. Pendergast SD, Trese MT. Familial exudative vitreoretinopathy. Results of surgical management. *Ophthalmology* 1998;105:1015-1023.
107. The Collaborative Ocular Melanoma Study Group. Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. COMS Report No. 6. *Am J Ophthalmol* 1998;125:745-766.
108. The Collaborative Ocular Melanoma Study Group.. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma. I. Characteristics of patients enrolled and not enrolled. COMS Report No. 9. *Am J Ophthalmol* 1998;125:767-778.
109. Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma. II. Initial mortality findings. COMS Report No. 10. *Am J Ophthalmol* 1998;125:779-796.
110. Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma. III. Local complications and observations following enucleation. COMS Report No. 11. *Am J Ophthalmol* 1998;126:362-372.
111. Pendergast SD, Trese MT. Ocular findings in cutis telangiectatica congenita. Bilateral vitreoretinopathy. *Retina* 1997;17:306-309.
112. Margherio RR, Margherio AR, Pendergast SD, Williams GA, Garretson BR, Strong LE. Vitrectomy for retained lens fragments following phacoemulsification. *Ophthalmology* 1997;104:1426-1432.
113. Shastry BS, Pendergast SD, Hartzler MK, Trese MT. Identification of a missense mutation in the Norrie's disease gene associated with advanced retinopathy of prematurity. *Arch Ophthalmol* 1997;115: 651-655.
114. Pendergast SD, McCuen BW II. Visual field loss following macular hole surgery. *Ophthalmology* 1996;103:1069-1077.
100. Pendergast SD, Martin DF, McCuen BW II, Proia AD, Jaffe GJ. Removal of optic disc stalks during diabetic vitrectomy. *Retina* 1995;15: 25-28.
- 101.. Pendergast SD, Elliott D, Macheimer R. Retinal toxic effects following inadvertent intraocular injection of Celestone Soluspan. *Arch Ophthalmol* 1995;113: 1230-1231.

102. Pendergast SD, Shields MB. Reproducibility of optic nerve head topographical measurements with the Glaucoma-Scope. *J Glaucoma* 1995;4:170-176.
115. Pendergast SD, Shields MB. Reproducibility of optic nerve head topographical measurements with the Glaucoma-Scope. *J Glaucoma* 1995;4:170-176.

### **Book Chapters**

1. Pendergast SD, Shields MB. Reproducibility of optic nerve head topographical measurements with the Glaucoma-Scope. In Krieglstein GK (ed.). *Glaucoma Update V*. Heidelberg: Kaden; 1995.
2. Pendergast SD, Williams GA. Complications in macular hole surgery. In McCuen BW, Madreperla SA (eds.). *Macular Hole: Pathogenesis, Diagnosis and Treatment*. Boston: Butterworth Heineman; 1998:155-168.
3. Zegarra H, Singerman LJ, Pendergast SD. Central retinal vein occlusion. In Saer JB (ed.). *Vitreo-Retinal and Uveitis Update. Proceedings of the New Orleans Academy of Ophthalmology Symposium*. The Hague: Kugler Publications; 1998: 259-267.
4. Pendergast SD, Singerman LJ, Niffenegger JH, Zegarra H. Laser treatment of proliferative retinopathies. In Saer JB (ed.). *Vitreo-Retinal and Uveitis Update. Proceedings of the New Orleans Academy of Ophthalmology Symposium*. The Hague: Kugler Publications; 1998:97-121.
5. Niffenegger JH, Pendergast SD, Singerman LJ. Laser management of less common macular diseases. In Singerman LJ, Coscas G (eds.). *Current Techniques in Ophthalmic Laser Surgery*. Philadelphia: Current Medicine; 1999:111-128.
6. Niffenegger JH, Pendergast SD, Singerman LJ. Photocoagulation of other causes of choroidal neovascularization. In Singerman LJ, Coscas G (eds.). *Current Techniques in Ophthalmic Laser Surgery*. Philadelphia: Current Medicine; 1999:91-110.
7. Zegarra H, Finkelstein D, Singerman LJ, Niffenegger JH, Pendergast SD. Laser management of branch and central retinal vein occlusions. In Singerman LJ, Coscas G (eds.). *Current Techniques in Ophthalmic Laser Surgery*. Current Medicine; 1999:67-76.
8. Pendergast SD, Singerman LJ, Niffenegger JH, Zegarra H. Lasers in the treatment of proliferative retinopathies. In Singerman LJ, Coscas G (eds.). *Current Techniques in Ophthalmic Laser Surgery*. Philadelphia: Current Medicine; 1999:35-53.
9. Pendergast SD, Zakov ZN, Novak MA. Lasers in vitreous surgery. In Singerman LJ, Coscas G (eds.). *Current Techniques in Ophthalmic Laser Surgery*. Philadelphia: Current Medicine; 1999:153-163.

10. Pendergast SD, Singerman LJ. Choroidal ruptures. In Fraunfelder FT, Roy H (eds.). *Current Ocular Therapy*. Philadelphia: WB Saunders Company; 2000: 313-314.
11. Pendergast SD. Choroidal ruptures. In Fraunfelder FT, Roy H (eds.). *Current Ocular Therapy, 6<sup>th</sup> ed*. Philadelphia: WB Saunders Company; 2007:320-321.

### **Abstracts**

1. Charles JB, Wu G, Roh S-Y, Gutierrez J, Pendergast SD, Weiter JJ. Practice patterns in the treatment of diabetic retinopathy in a referral population. *Invest Ophthalmol Vis Sci* 1991;32 (suppl):1142.
2. Wu G, Pendergast SD, Roh S-Y, Gutierrez J, Brodie SE. ERG changes in patients with long-standing diabetes mellitus and early diabetic retinopathy. *Invest Ophthalmol Vis Sci* 1991; 32 (suppl):1029.
3. Pendergast SD, McCuen BW II. Visual field loss following macular hole surgery. *Ophthalmology* 1995;102 (suppl):91.
4. T. Hassan, Pendergast SD, Hartzer M, Cheng M. Effect of intravitreal suramin on a rabbit model of proliferative vitreoretinopathy. *Invest Ophthalmol Vis Sci* 1996;37 (suppl):1824.
5. Pendergast SD, Hartzer M, Dailey W, Williams GA, M Cheng M, Trese MT. Fluid-gas exchange following intravitreal plasmin injection in a rabbit model. *Invest Ophthalmol Vis Sci* 1996;37 (suppl):913.
6. Pendergast SD, Trese MT. Surgical management of familial exudative vitreoretinopathy. *Ophthalmology* 1996;103 (suppl):126.

### **Posters**

1. Rostamizadeh M, Abdelaziz M, Patel A, Moarefi M, Miller D, Coney J, Novak M, Rao L, Pendergast S, Singerman L. Incidence of endophthalmitis in various anti-VEGF treatments. Scientific Poster 5025/ B0231, Association for Research in Vision and Ophthalmology Annual Meeting, May 2016.
2. Wu G, Pendergast SD, Roh S-Y, Gutierrez J, Brodie SE. ERG changes in patients with long-standing diabetes and early diabetic retinopathy (poster). ARVO Meeting, Sarasota, Florida. May 5, 1991.